FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient. A2B694 therapy was well tolerated, showing no dose-limiting toxicities and ...

The MarketWatch News Department was not involved in the creation of this content. Strategy May Bolster Blood Cancer Therapy and Move HIV Research Closer to a Cure BRONX, N.Y., March 13, 2026 ...

A method called **‘in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)’** that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...